Table 1 Descriptive statistics
Characteristic | Pertuzumab-pretreated (n = 23) | Pertuzumab-naive (n = 10) | P value* |
|---|---|---|---|
Months from initial | median: 23.5 | median: 14.7 | 0.763 |
Dx to Met Dx | range: 0.0–192.5 | range: 0.0–53.6 | |
Initial Dx of Met | No: 13 (56.5%) | No: 8 (80.0%) | 0.259 |
disease | Yes: 10 (43.5%) | Yes: 2 (20.0%) | |
Age at Met Dx | median: 58.0 | median: 52.0 | 0.377 |
range: 34.0–86.0 | range: 38.0–67.0 | ||
Ethnicity | white: 20 (87.0%) | white: 9 (90.0%) | 1.000 |
black: 3 (13.0%) | black: 1 (10.0%) | ||
Num. prior therapies | median: 1.0 | median: 1.0 | 0.586 |
in Met setting | range: 0.0–8.0 | range: 0.0–7.0 | |
Num. prior therapies | 0: 6 (26.1%) | 0: 1 (10.0%) | 0.397 |
in Met setting (binary) | > = 1: 17 (73.9%) | > = 1: 9 (90.0%) | |
Brain mets | No: 13 (56.5%) | No: 6 (60.0%) | 1.000 |
(at T-DM1 start) | Yes: 10 (43.5%) | Yes: 4 (40.0%) | |
Bone mets | No: 8 (34.8%) | No: 6 (60.0%) | 0.257 |
(at T-DM1 start) | Yes: 15 (65.2%) | Yes: 4 (40.0%) | |
Lung mets | No: 7 (30.4%) | No: 9 (90.0%) | 0.002 |
(at T-DM1 start) | Yes: 16 (69.6%) | Yes: 1 (10.0%) | |
Liver mets | No: 12 (52.2%) | No: 6 (60.0%) | 0.722 |
(at T-DM1 start) | Yes: 11 (47.8%) | Yes: 4 (40.0%) | |
HR+ (ER+ or PR+) | No: 12 (52.2%) | No: 2 (25.0%) | 0.240 |
at metastasis | Yes: 11 (47.8%) | Yes: 6 (75.0%) | |
Months from Met Dx | median: 12.6 | median: 8.2 | 0.845 |
to T-DM1 therapy | range: 0.3–69.8 | range: 0.4–60.2 | |
Months from Met Dx | < 10: 10 (43.5%) | < 10: 6 (60.0%) | 0.465 |
to T-DM1 (binary) | > = 10: 13 (56.5%) | > = 10: 4 (40.0%) | |
Months of T-DM1 | median: 2.9 | median: 4.8 | 0.799 |
therapy | range: 0.7–50.4 | range: 0.7–40.8 | |
T-DM1 dose | No: 18 (78.3%) | No: 9 (90.0%) | 0.640 |
reduction | Yes: 5 (21.7%) | Yes: 1 (10.0%) | |
Cardiac toxicity | No: 22 (95.7%) | No: 8 (80.0%) | 0.212 |
(during T-DM1) | Yes: 1 (4.3%) | Yes: 2 (20.0%) | |
Neuropathy | No: 21 (91.3%) | No: 9 (90.0%) | 1.000 |
(during T-DM1) | Yes: 2 (8.7%) | Yes: 1 (10.0%) | |
T-DM1 discontinuation | No: 22 (95.7%) | No: 9 (90.0%) | 0.521 |
due to toxicity | Yes: 1 (4.3%) | Yes: 1 (10.0%) | |
Overall response | No: 18 (85.7%) | No: 7 (70.0%) | 0.358 |
(CR or PR) | Yes: 3 (14.3%) | Yes: 3 (30.0%) | |
CBR (CR, PR, or SD | No: 10 (47.6%) | No: 5 (50.0%) | 1.000 |
with T-DM1 > 6 mo) | Yes: 11 (52.4%) | Yes: 5 (50.0%) |